Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-26 02:08 | 2025-11-25 | EQ | Equillium, Inc. | Zedelmayer Christine | Officer | SELL | $0.95 | 8,098 | $7,696 | 127,148 |
| 2025-11-26 00:11 | 2025-11-21 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer | SELL | $19.78 | 14,328 | $283,408 | 27,737 |
| 2025-11-26 00:10 | 2025-11-21 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | Officer | SELL | $35.00 | 3,427 | $119,945 | 0 |
| 2025-11-26 03:00 | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Zawitz David | Officer | BUY | $4.24 | 10,000 | $42,425 | 21,000 |
| 2025-11-26 03:00 | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Rieger Jayson | Director, Officer | BUY | $4.24 | 94,311 | $400,114 | 182,593 |
| 2025-11-26 02:04 | 2025-11-21 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $0.92 | 195,666 | $179,543 | 5,125,770 |
| 2025-11-26 00:02 | 2025-11-21 | ALMS | Alumis Inc. | Tananbaum James B. | Director, 10% owner | BUY | $7.38 | 72,212 | $532,925 | 2,614,215 |
| 2025-11-26 03:00 | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Rosenberg Noah L. | Officer | BUY | $4.24 | 2,357 | $10,000 | 2,357 |
| 2025-11-26 03:00 | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Kirby John J. | Officer | BUY | $4.24 | 3,536 | $15,001 | 8,962 |
| 2025-11-26 01:35 | 2025-11-21 | VSTM | Verastem, Inc. | Bunn Paul A. | Director | OPT+S | $10.00 | 6,250 | $62,500 | 2,083 |
| 2025-11-26 01:32 | 2025-11-21 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $10.00 | 6,000 | $60,000 | 432,818 |
| 2025-11-26 03:00 | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Director, 10% owner | BUY | $4.24 | 4,126,142 | $17,505,157 | 3,348,372 |
| 2025-11-26 00:38 | 2025-11-21 | ARDX | Ardelyx Inc. | Kelliher Mike | Officer | SELL | $5.54 | 5,560 | $30,785 | 271,181 |
| 2025-11-26 00:35 | 2025-11-21 | ARDX | Ardelyx Inc. | Williams Laura A | Officer | SELL | $5.54 | 6,426 | $35,580 | 359,896 |
| 2025-11-26 00:22 | 2025-11-21 | ARDX | Ardelyx Inc. | Foster Eric Duane | Officer | SELL | $5.54 | 5,814 | $32,192 | 295,684 |
| 2025-11-26 00:21 | 2025-11-21 | ARDX | Ardelyx Inc. | Reilly Joseph James | Officer | SELL | $5.54 | 11,086 | $61,382 | 108,914 |
| 2025-11-26 04:17 | 2025-11-25 | COCP | Cocrystal Pharma, Inc. | FROST PHILLIP MD ET AL | Director, 10% owner | BUY | $0.94 | 20,000 | $18,812 | 1,699,551 |
| 2025-11-26 01:34 | 2025-11-21 | VSTM | Verastem, Inc. | Kauffman Michael | Director | SELL | $10.00 | 8,550 | $85,500 | 8,666 |
| 2025-11-26 00:42 | 2025-11-21 | ARDX | Ardelyx Inc. | RAAB MICHAEL | Director, Officer | SELL | $5.54 | 46,887 | $259,609 | 1,455,363 |
| 2025-11-26 05:20 | 2025-11-24 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $3.94 | 535 | $2,105 | 0 |
| 2025-11-25 20:26 | 2025-11-24 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | BUY | $4.08 | 39,200 | $159,885 | 2,519,739 |
| 2025-11-26 02:59 | 2025-11-24 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | BUY | $4.08 | 39,200 | $159,885 | 2,529,739 |
| 2025-11-26 00:10 | 2025-11-21 | MIRM | Mirum Pharmaceuticals, Inc. | GREY MICHAEL G | Director | OPT+S | $70.00 | 50,000 | $3,500,000 | 0 |
| 2025-11-26 00:44 | 2025-11-21 | ARDX | Ardelyx Inc. | GRAMMER ELIZABETH A | Officer | SELL | $5.54 | 5,995 | $33,194 | 299,895 |
| 2025-11-26 01:00 | 2025-11-21 | TYRA | Tyra Biosciences, Inc. | MORE ROBERT J | Director | SELL | $20.25 | 246,871 | $5,000,026 | 3,833,425 |
| 2025-11-26 04:28 | 2025-11-25 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $54.28 | 2,207 | $119,796 | 54,245 |
| 2025-11-26 02:05 | 2025-11-21 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.92 | 125,576 | $115,229 | 3,287,551 |
| 2025-11-26 02:03 | 2025-11-21 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $0.92 | 195,666 | $179,543 | 5,125,770 |
| 2025-11-26 00:49 | 2025-11-24 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $473.05 | 8,000 | $3,784,418 | 130 |
| 2025-11-26 01:20 | 2025-11-21 | PTCT | PTC THERAPEUTICS, INC. | Reeve Emma | Director | OPT+S | $79.50 | 10,000 | $795,000 | 6,666 |
| 2025-11-26 00:06 | 2025-11-24 | SAVA | FILANA THERAPEUTICS, INC. | Anderson Robert Eugene Jr | Director | BUY | $2.90 | 8,600 | $24,940 | 8,600 |
| 2025-11-26 03:38 | 2025-11-25 | AMPH | Amphastar Pharmaceuticals Inc. | PRINS RICHARD K | Director | OPT+S | $27.10 | 4,179 | $113,253 | 35,183 |
| 2025-11-26 05:00 | 2025-11-24 | TTRX | Turn Therapeutics Inc. | GOLDEN ARTHUR F | Director | BUY | $3.44 | 9,868 | $33,946 | 60,602 |
| 2025-11-26 01:31 | 2025-11-24 | TGTX | TG THERAPEUTICS, INC. | Echelard Yann | Director | SELL | $32.57 | 5,000 | $162,850 | 223,816 |
| 2025-11-25 00:00 | 2025-11-21 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,058.66 | 105,326 | $111,504,097 | 92,501,978 |
| 2025-11-25 00:03 | 2025-11-20 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | Officer | OPT+S | $24.78 | 28,229 | $699,523 | 63,647 |
| 2025-11-25 01:46 | 2025-11-20 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Neman-Ebrahim Yousha | Officer | BUY | $6.69 | 1,100 | $7,359 | 134,260 |
| 2025-11-25 00:08 | 2025-11-20 | NUVB | Nuvation Bio Inc. | Liu Dongfang | Officer | OPT+S | $7.00 | 20,000 | $140,074 | 18,000 |
| 2025-11-25 02:45 | 2025-11-21 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd | Director, Officer | SELL | $30.35 | 50,000 | $1,517,405 | 740,537 |
| 2025-11-25 02:46 | 2025-11-20 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $65.84 | 26,156 | $1,722,224 | 228,776 |
| 2025-11-25 00:30 | 2025-11-21 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | Officer | SELL | $9.98 | 8,910 | $88,932 | 110,026 |
| 2025-11-25 00:05 | 2025-11-20 | REGN | REGENERON PHARMACEUTICALS, INC. | Bassler Bonnie L | Director | OPT+S | $750.00 | 760 | $570,000 | 1,548 |
| 2025-11-25 00:15 | 2025-11-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Cramer Pamela J. | Officer | OPT+S | $105.00 | 3,350 | $351,750 | 20,814 |
| 2025-11-25 02:00 | 2025-11-21 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $0.80 | 22,000 | $17,600 | 756,460 |
| 2025-11-25 02:06 | 2025-11-24 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $17.07 | 37,600 | $641,697 | 50,897 |
| 2025-11-25 00:09 | 2025-11-20 | NUVB | Nuvation Bio Inc. | Hattersley Gary | Officer | OPT+S | $7.23 | 369,051 | $2,667,132 | 0 |
| 2025-11-25 00:42 | 2025-11-20 | GRTX | Galera Therapeutics, Inc. | Sorensen Mel | Director, Officer | SELL | $0.02 | 70,000 | $1,407 | 195,029 |
| 2025-11-25 05:10 | 2025-11-21 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Heshmatpour Amir F | Director, Officer, 10% owner | BUY | $6.16 | 30,000 | $184,659 | 2,992,000 |
| 2025-11-25 01:43 | 2025-11-20 | SION | Sionna Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | SELL | $39.61 | 30,316 | $1,200,705 | 159,033 |
| 2025-11-24 20:54 | 2025-11-21 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $1.14 | 5,000 | $5,700 | 281,421 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.